The yellow fever 17D vaccine virus: Molecular basis of viral attenuation and its use as an expression vector

被引:17
|
作者
Galler, R [1 ]
Freire, MS [1 ]
Jabor, AV [1 ]
Mann, GF [1 ]
机构
[1] FIOCRUZ MS, LAB TECNOL VIROL, INST TECNOL IMUNOBIOL, BR-21045900 RIO DE JANEIRO, BRAZIL
关键词
flavivirus; yellow fever virus; attenuation; vaccine; gene expression;
D O I
10.1590/S0100-879X1997000200002
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The yellow fever (YF) virus is the prototype flavivirus. The use of molecular techniques has unraveled the basic mechanisms of viral genome structure and expression. Recent trends in flavivirus research include the use of infectious clone technology with which it is possible to recover virus from cloned cDNA. Using this technique, mutations can be introduced at any point of the viral genome and their resulting effect on virus phenotype can be assessed. This approach has opened new possibilities to study several biological viral features with special emphasis on the issue of virulence/attenuation of the YF virus. The feasibility of using YF virus 17D vaccine strain, for which infectious cDNA is available, as a vector for the expression of heterologous antigens is reviewed.
引用
收藏
页码:157 / 168
页数:12
相关论文
共 50 条
  • [21] IFNγ attenuates of yellow fever virus 17D vaccine strain in vivo and its implication for severe adverse events
    Lam, Long Kwan Metthew
    Watson, Alan
    Klimstra, William
    Ryman, Kate
    [J]. JOURNAL OF IMMUNOLOGY, 2014, 192
  • [22] A Yellow Fever 17D Virus Replicon-Based Vaccine Platform for Emerging Coronaviruses
    Oreshkova, Nadia
    Myeni, Sebenzile K.
    Mishra, Niraj
    Albulescu, Irina C.
    Dalebout, Tim J.
    Snijder, Eric J.
    Bredenbeek, Peter J.
    Dallmeier, Kai
    Kikkert, Marjolein
    [J]. VACCINES, 2021, 9 (12)
  • [23] Is a dose of 17D vaccine in the current context of Yellow Fever enough?
    Estofolete, Cassia Fernanda
    Nogueira, Mauricio Lacerda
    [J]. BRAZILIAN JOURNAL OF MICROBIOLOGY, 2018, 49 (03) : 683 - 684
  • [24] Stability-related studies on 17D yellow fever vaccine
    Perraut, R
    Girault, G
    Moreau, JP
    [J]. MICROBES AND INFECTION, 2000, 2 (01) : 33 - 38
  • [25] A Yellow Fever Virus 17D Infection and Disease Mouse Model Used to Evaluate a Chimeric Binjari-Yellow Fever Virus Vaccine
    Yan, Kexin
    Vet, Laura J.
    Tang, Bing
    Hobson-Peters, Jody
    Rawle, Daniel J.
    Le, Thuy T.
    Larcher, Thibaut
    Hall, Roy A.
    Suhrbier, Andreas
    [J]. VACCINES, 2020, 8 (03) : 1 - 14
  • [26] Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model
    Tao, D
    Barba-Spaeth, G
    Rai, U
    Nussenzweig, V
    Rice, CM
    Nussenzweig, RS
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (02): : 201 - 209
  • [27] THE USE OF A STABILIZED YELLOW-FEVER 17D VACCINE DURING THE 1983 YELLOW-FEVER EPIDEMIC IN BURKINA FASO
    SALUZZO, JF
    SOME, L
    BAUDON, D
    GIRAULT, G
    LHUILLIER, M
    KAMBIRE, PA
    ROUX, JF
    DIGOUTTE, JP
    [J]. BULLETIN DE LA SOCIETE DE PATHOLOGIE EXOTIQUE, 1985, 78 (04): : 536 - 540
  • [28] Harnessing the attenuated yellow fever virus 17D strain for Epstein Barr virus specific vaccine development
    Valencia, A.
    Ruhl, J.
    Schuhmachers, P.
    Boudewijns, R.
    Dallmeier, K.
    Munz, C.
    [J]. SWISS MEDICAL WEEKLY, 2021, 151 : 5S - 5S
  • [29] Genetic variability among yellow fever virus 17D substrains
    Galler, R
    Post, PR
    Santos, CND
    Ferreira, II
    [J]. VACCINE, 1998, 16 (9-10) : 1024 - 1028
  • [30] Comparing immunogenicity and protective efficacy of the yellow fever 17D vaccine in mice
    Ma, Ji
    Boudewijns, Robbert
    Sanchez-Felipe, Lorena
    Mishra, Niraj
    Vercruysse, Thomas
    Buh Kum, Dieudonne
    Thibaut, Hendrik Jan
    Neyts, Johan
    Dallmeier, Kai
    [J]. EMERGING MICROBES & INFECTIONS, 2021, 10 (01) : 2279 - 2290